A092105
Trial Overview
Official Title
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Advanced Nasopharyngeal Cancer
Study Purpose
To determine if progression-free survival is more favorable with triplet therapy combination of Cabozantinib + Nivolumab + Ipilimumab than with doublet therapy combination of Nivolumab + Ipilimumab
Diagnosis
Recurrent, metastatic and incurable Nasopharyngeal CarcinomaEligibility
1-2 prior lines of treatment with platinum-gemcitabine and PD-L1 blocker, with immunotherapy as part of the most recent treatment regimen
Intervention
Arm A: Nivolumab + Ipilimumab. Arm B: Cabozantinib + Nivolumab + Ipilimumab.
For more information visit Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
18 years and Older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
A092105